Background: Women with unilateral breast cancer (UBC) are at risk of developing a subsequent contralateral breast cancer (CBC). Common variants are associated with breast cancer risk. Whether these influence CBC risk is unknown. Methods: Participants were breast cancer cases from the population-based Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. Sixty-seven established breast cancer risk loci were genotyped directly or by imputation in 1459 case subjects with CBC and 2126 UBC control subjects. An unweighted polygenic risk score (PRS) was created by summing the number of risk alleles for each directly genotyped single nucleotide polymorphism (SNP), or for imputed loci, the imputed dosage. A weighted PRS was calculated similarly, but where each SNP's contribution was weighted by the published per-allele log odds ratio. Unweighted and weighted polygenic risk scores and CBC risk were modeled using conditional logistic regression. Cumulative CBC risk was estimated and benchmarked using Surveillance, Epidemiology, and End Results population incidence rates. Results: Both unweighted and weighted PRS were statistically significantly associated with CBC risk. The adjusted risk ratio of CBC in women in the upper quartile of unweighted PRS compared with the lowest quartile was 1.63 (95% confidence interval [CI] ¼ 1.33 to 2.00). The estimated 10-year cumulative risk for women in the upper quartile of the unweighted PRS was 7.4% (95% CI ¼ 6.0% to 9.1%). For women in the upper quartile of the weighted PRS, the risk ratio for CBC was 1.75 (95% CI ¼ 1.41 to 2.18) compared with women in the lowest quartile. There was no statistically significant heterogeneity by age, treatment (radiation therapy dose, tamoxifen, chemotherapy), estrogen receptor status of the first primary, histology of the first primary, length of at-risk period for CBC, or breast cancer family history.
Conclusions: Common genomic variants associated with the development of first primary breast cancer are also associated with the development of CBC; the risk is strongest among those who carry more risk alleles.
Women with unilateral breast cancer (UBC) are at increased risk of developing a second primary cancer in the contralateral breast. A number of factors are associated with higher risks of contralateral breast cancer (CBC) (1, 2) , and models incorporating these factors can be used to derive individualized risk estimates (3) . Such estimates could be used to facilitate understanding of personal risk by women considering contralateral preventive mastectomy to reduce their likelihood of developing a second cancer.
It is clear that genetic factors influence the risk of CBC. The risk is particularly high in women with rare high-penetrance sequence variants, such as mutations in BRCA1 or BRCA2, where the 10-year risk may approach 25% to 30% (4, 5) . Mutations in CHEK2 also increase the risk of CBC, albeit to a lesser degree (6, 7) , and rare pathogenic PALB2 mutations have also been shown to increase the risk of CBC (8, 9) . In some family studies and within subgroups of breast cancer patients, rare mutations in the ATM gene have also been shown to increase the risk of CBC (10, 11) . Genome-wide association studies have found a number of common variants (single nucleotide polymorphisms [SNPs] ) associated with the development of breast cancer. A recent metaanalysis characterized more than 90 SNPs linked to breast cancer risk in the general population (12) . An individual woman's risk for breast cancer may be related to the number of risk variants that she carries and can be represented by a summary polygenic risk score (PRS) that is derived from her genotypes at each locus (13) .
The common SNPs associated with breast cancer were identified in case-control studies comparing women with a first primary breast cancer with those without breast cancer. An earlier study found that some of these variants modified risk of CBC (14) , but no study has yet evaluated the discriminatory potential of a PRS derived from a larger number of SNPs. The current report describes an analysis of the association between CBC and the overall "genomic burden" of common risk variants using the resources of the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study, a population-based study of women with UBC or CBC that was designed to evaluate the impact of genetic factors on CBC risk. This evaluation is a necessary first step toward incorporating personal genomic information into a model for calculating an estimate of individual CBC risk.
Methods

Study Population
The WECARE Study is an institutional review board-approved population-based case-control study of women younger than age 55 years at first diagnosis of invasive breast cancer in which case subjects have asynchronous CBC and control subjects have UBC (15) . The study recruitment and data collection occurred in two phases, WECARE I (2001-2004) and WECARE II (2009-2012), using nearly identical study procedures in seven study centers. Five US study centers recruited women from cancer registries that contribute to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry program: Northern California, Los Angeles County, Orange County/San Diego, Seattle, and Iowa. Additional population-based recruitment and data collection were conducted in Denmark and Ontario, Canada.
Eligible CBC case subjects were women who 1) were diagnosed between 1985 and 2008 with a first invasive breast cancer that did not spread beyond regional lymph nodes at diagnosis and a second contralateral primary breast cancer at least one year (two years in WECARE II) after the first breast cancer diagnosis; 2) were younger than age 55 years at first diagnosis; 3) had no previous or intervening cancer diagnosis except nonmelanoma skin cancer; 4) were alive at the time of contact and able to provide informed consent to complete the interview and to provide a biospecimen; and 5) resided in the same cancer registry reporting region for both diagnoses. Eligible control subjects with an intact contralateral breast were identified using the same eligibility criteria and individually matched to cases (1:2 in WECARE I; 1:1 in WECARE II) on the following criteria: year of birth (in five-year strata), year of diagnosis (four-year strata), cancer registry region, and race/ethnicity. For cases, the reference date was defined as the date of the patient's second breast cancer diagnosis. The time between a case subject's first breast cancer and her CBC defined her at-risk period. For a matched control subject, her case subject's at-risk period was added to the control's date of UBC, and the date on which the at-risk period ended defined her reference date. WECARE I case and control subjects were countermatched on radiation exposure, such that two members of the case-control triad had received radiation therapy for their index breast cancer. In total, 2354 CBC case subjects and 3599 UBC control subjects met eligibility criteria and were approached for inclusion in the study. Of eligible women, 1521 case subjects (64.6%) and 2212 control subjects (61.5%) completed the interview, provided a biospecimen (blood or saliva), and provided written informed consent. All WECARE Study participants were interviewed by telephone using the same questionnaire, and medical records, pathology reports, and hospital charts were used to collect detailed treatment information (ie, chemotherapy, hormonal therapy, and radiation therapy) and tumor characteristics. Characteristics of the study participants included in the current report are presented in Table 1 . Race/ethnicity is based on self-report.
Genotyping
DNA from WECARE I Study participants was prepared from blood samples by red cell lysis and standard methods of phenol/ chloroform extraction (16, 17) . Samples were genotyped with Illumina's HumanOmni1-Quad BeadChip (Illumina Inc., San Diego, CA) as part of the WECARE Study's genome-wide association study effort. Default Omni1-Quad cluster definitions supplied by Illumina were used to call genotypes. Each 96-well plate included one interplate positive quality control sample (NA06990, Coriell Cell Repositories, Camden, NJ). In addition, 38 blinded and 46 unblinded quality control replicates from the study sample were genotyped. Concordance rates for both the Coriell and study sample replicates were greater than 99.99%. DNA from WECARE II Study participants was prepared from saliva samples using standard methods. Samples were genotyped on two custom oligonucleotide probe panels using the Infinium iSelect HD Custom Bead Chip (Illumina Inc.).
Genotype data were cleaned based on quality control (QC) metrics at the individual sample and SNP levels. Samples with a less than 95% call rate, low concordance with previous genotype data, duplicate samples, unanticipated genotype concordance, identity-by-descent (IBD) with another sample, or ethnic outliers as identified by visual inspection of PCA cluster plots were ARTICLE removed. After exclusion of samples failing QC, final unweighted analyses were conducted in all races on 1459 CBC cases and 2126 UBC controls. Final weighted analyses were conducted on 1290 non-Hispanic white CBC case subjects and 1906 non-Hispanic white UBC control subjects.
Individual genotypes were determined at 67 polymorphic loci that were known to be associated with breast cancer risk at the time of analysis (32 directly genotyped and 34 imputed; one SNP was genotyped in WECARE I only). Prior to imputation, SNPs with GenTrain scores of less than 0.36, a less than 95% call rate, concordance of less than 95% with 1000 Genomes in samples genotyped for quality control, or Hardy-Weinberg equilibrium (HWE) P values of less than 10 -5 in controls were excluded. All SNPs overlapping 1000 Genomes were matched to the forward strand. IMPUTE2 was used to impute missing genotypes for WECARE I and II study samples based on the cosmopolitan panel of reference haplotypes from phase I of the 1000 Genomes Project (March 2012 release; n ¼ 1092) (18) . Genetic markers resulting from the imputation of the 34 loci had to pass stringent imputation quality and accuracy filters prior to entering the analysis phase (info 0.7, certainty 0.9, and, for genotyped markers only, concordance 0.9 between directly measured and imputed genotypes after masking input genotypes). The median quality score for imputed SNPs was 1, with all being greater than 0.4, and 31 of 34 being greater than 0.75. In addition to SNP genotyping, screening for mutations in BRCA1, BRCA2, ATM, CHEK2, and PALB2 was performed for WECARE I participants only. Population substructure was investigated using EIGENSTRAT generating principal components to include in analyses (19) . Identity by descent was examined using PLINK (20) , identifying three pairs of sisters, including one pair of identical twins in WECARE I.
Statistical Analysis
Derivation of Unweighted and Weighted Polygenic Risk Scores Individual genomic risk was assessed in two ways. For each study participant, genotypes were determined at loci published as being associated with breast cancer risk in the iCOGs study, the most comprehensive genome-wide analysis prior to the recently published meta-analysis (21) . An unweighted risk score was calculated as the integer count of risk alleles at each directly genotyped locus, or for imputed loci, the imputed dosage (values between 0 and 2, inclusive). If the published minor allele odds ratio (OR) was less than 1, the major allele was considered the risk allele for this calculation. A weighted PRS was also calculated as the sum of the minor alleles weighted by the per-allele log odds ratio using the method described by Mavaddat et al. and odds ratio estimates from the iCOGs study (13) . Weighted scores were only calculated for non-Hispanic white women as published studies that derived the odds ratios used for calculation of these scores were largely comprised of women of European ancestry and the per-allele odds ratios for nonwhite women are not as well established. Supplementary Table 1 (available online) describes the SNPs chosen for the unweighted and weighted analyses and the odds ratios employed.
Evaluation of Association Between PRS and CBC Risk
The associations of PRS with CBC risk were computed based on quartiles of unweighted or weighted risk scores across all study participants. Multivariable-adjusted risk ratios (RRs) and corresponding 95% confidence intervals (CIs) were estimated by fitting conditional logistic regression models. Models were adjusted for exact age at first breast cancer diagnosis (continuous) and eigenvectors (four in analyses including all women and three in those including only non-Hispanic white women), and then also for risk factors for CBC, including age at menarche (<13 years, 13 years, missing), number of full-term pregnancies (nulliparous, one, two, three, four or more, missing), menopausal status one year prior to first diagnosis (premenopausal, postmenopausal <45 years, postmenopausal 45 years, missing), family history of breast cancer (yes, no, adopted/missing), were genotyped for CHEK2 1100delC. A total of 578 CBC cases and 575 UBC controls were genotyped for mutations in PALB2. These frequencies are from a subset of WECARE I participants with known PRS. ‡Three CBC cases and two UBC controls had at least one BRCA1 or BRCA2 mutation but had unknown PRS information. §One CBC case had deleterious mutations in both BRCA and CHEK2 1100delC. One UBC control had deleterious mutations in both BRCA and ATM.
histology of first breast cancer (lobular, other, missing), stage of first diagnosis (local, regional), and chemotherapy/hormonal treatment for first breast cancer (yes, no). For the unweighted PRS models, trend was assessed two ways: 1) across quartiles (assigning 1, 2, 3, and 4 to respective quartiles) and 2) using the per-allele count. For the weighted PRS models, trend was assessed two ways: 1) across quartiles and 2) using the perweighted allele count. Heterogeneity of the PRS by variables of interest was assessed across quartiles using likelihood ratio tests for nested models. Heterogeneity was also assessed for quartile trend (as described above) by variables of interest. Heterogeneity of the PRS by WECARE I and II Study phases was assessed as described above; because no statistically significant heterogeneity was found, data from the two study phases were combined for the analyses presented here. Cumulative absolute risks of CBC were estimated by previously described methodology employing relative risks from WECARE Study data combined with population-based SEER*Stat cancer incidence data for women age 18 to 54 years diagnosed between 1985 and 2008 for comparability with women in the WECARE Study (SEER*Stat ref: http://seer.cancer.gov/data/citation.html) (3, 4, 22) . All P values were two-sided, and any P values of less than .05 were considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
Results
Among all WECARE I and WECARE II Study participants, the absolute number of risk alleles (unweighted score) was associated with an increased risk of developing CBC (Table 2 ). For the quartile of women with the highest burden of risk alleles, the adjusted risk ratio of developing CBC compared with the lowest quartile was 1.63 (95% CI ¼ 1.33 to 2.00). The per risk allele trend risk ratio was 1.04 (95% CI ¼ 1.03 to 1.06). There was no statistically significant heterogeneity in association by age at first diagnosis, radiation dose for the first breast cancer, family history of breast cancer, estrogen receptor status of the first breast cancer, or tamoxifen treatment for the first breast cancer (data not shown). The estimated 10-year cumulative risk in women with unweighted scores in the upper quartile was 7.4% (95% CI ¼ 6.0% to 9.1%), compared with 4.6% (95% CI ¼ 4.1% to 5.2%) for women in the lowest quartile. Carriers of mutations in other predisposing genes such as BRCA1/2, ATM, CHEK2, and PALB2 have previously been identified among WECARE I Study participants, 127 CBC case subjects (20% of those genotyped) and 91 control subjects (9% of those genotyped) (4, 6, 9, 23, 24) . Among women screened negative for mutations in these genes, the association of the unweighted risk allele score with CBC risk remained statistically significant (Table 3) . Noncarriers with unweighted scores in the upper quartile of the distribution had an adjusted risk ratio for CBC of 1.91 (95% CI ¼ 1.29 to 2.82) compared with women in the lowest quartile.
There was a statistically significant association between weighted PRS and CBC risk (Table 4) . For white women with PRS in the upper quartile of weighted PRS, the risk ratio for developing CBC was 1.75 (95% CI ¼ 1.41 to 2.18), compared with women in the lowest quartile. The per-one-unit change in weighted allele score risk ratio was 1.66 (95% CI ¼ 1.39 to 1.97). There was no heterogeneity in association by age at first diagnosis, radiation dose for the first breast cancer, family history of breast cancer, estrogen receptor status of the first breast cancer, histology of the first breast cancer, length of at-risk period for CBC, or tamoxifen treatment for the first breast cancer (not shown).
Discussion
The current study establishes that a risk score that reflects the aggregate burden of genetic variations that are associated with the development of first primary breast cancer is also associated with the development of contralateral second primary cancers. The WECARE Study ascertainment was population based and has served as the basis of a number of studies examining the association between clinical and genetic factors and CBC risk (3, 4, 6, 9, 14, (23) (24) (25) The derived risk ratios from this study can therefore easily and meaningfully be incorporated into risk prediction models that combine genomic, clinical, and epidemiologic risk factors.
Several investigators have reported an increase in the proportion of women undergoing contralateral prophylactic mastectomy (CPM) (26, 27) . The reasons for this increase are not well understood, but a misperception of the risk of CBC may contribute (28) . Genetic factors are known to be important influences on CBC risk, and germline mutations in BRCA1 or BRCA2, while histology at first diagnosis, menopausal status one year prior to first diagnosis, age at menarche, number of full-term pregnancies at first diagnosis, hormonal and chemotherapy treatment for the first primary, and family history of breast cancer.
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rare, are particularly strong risk factors (4, 5) . Peri-diagnostic assessment of BRCA1/2 mutation status can substantially impact decision-making with respect to CPM, but many women undergoing CPM do not carry mutations in these genes. The present study establishes that a PRS derived from more common genetic variants influences CBC risk. Individual genotyping could be used to provide women without BRCA mutations with a personalized assessment of their contralateral risk. More accurate risk prediction would aid women considering CPM. In particular, women at average or low levels of genetic risk could be reassured that their likelihood of developing CBC is sufficiently low to forego consideration of more extensive surgery. We were able to conduct analyses with imputed genotypes at loci that were not directly genotyped, increasing the discriminatory power of the PRS. However, the low probability of misimputation could lead to incorrect classification of individuals for the minority of SNPs that were imputed; however, to the extent that this is true, it would bias the results toward the null. Furthermore, new breast cancer risk SNPs continue to emerge. Our study employed 67 SNPs to construct the PRS, but there are now over 90 loci at which common variants are associated with breast cancer risk (12) . PRS constructed with additional loci could reclassify some individuals although the incremental effect of each locus is likely to be small.
The association between common variants and CBC risk appeared to be similar across strata of previously identified risk factors, including age, treatment effects, and hormone receptor status. The impact was similar in younger and older women, recognizing that the WECARE ascertainment is confined to women diagnosed with their first breast cancer younger than age 55 years. The risk ratio was also similar in women with or without a family history of breast cancer and was observed in WECARE I Study women without pathogenic mutations in cancer predisposition genes. This indicates that the polygenic risk represented by the common variant risk allele burden is likely to be independent of the risk conferred by higher penetrance variants. The number of rare mutation carriers in this study was too small to assess whether the PRS is associated with breast cancer risk in these women. This important question requires a dedicated study in carriers of genes such as BRCA1 and BRCA2. If the PRS is associated with CBC risk in these women, risk allele genotyping could also assist those patients in decision-making with respect to CPM.
There are some limitations to the present study. The majority of participants in the WECARE Study were non-Hispanic white, and the applicability of the findings to nonwhite populations requires confirmation. In particular, the weighted PRSs were calculated using per-allele odds ratios that were reported in studies of predominantly European women, and the quartiledefining values of PRS may differ in nonwhite women. We included nonwhite women in our analysis of the association of unweighted risk allele count with CBC risk, making the assumption that the loci linked to risk would be the same among all women but that the absolute risk resulting from the genotype at a locus may vary with ancestry because of epistatic effects. The association between unweighted risk allele count and CBC risk was statistically significant in women of all races/ethnicities, as well as among self-reported white women.
In summary, the present study demonstrates that the cumulative genomic burden of common breast cancer risk variants increases the risk of CBC. This holds true whether one assesses the integer count of number of risk variants (unweighted analysis) or a derived polygenic risk score that is calculated using published per-allele odds ratios for the variants. The case-control study design does not allow direct observation of absolute risks in the different quartiles of unweighted or weighted risk scores. However, the relative risks derived in this study could be used in developing absolute risk prediction models to aid women facing the decision whether to undergo CPM. The development and deployment of such models in response to the observed increase in the rate of CPM could help focus this intervention on those women at highest risk for CBC and allow those at low levels of risk to avoid more extensive and likely unhelpful surgery.
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